Join­ing forces with Sky­hawk, C4 Ther­a­peu­tics, Bio­gen buys more shots on goal on SMA, Alzheimer's

These days at Bio­gen, the spot­light tends to fall on one of two pro­grams: Its com­mer­cial SMA drug Spin­raza, and the ex­per­i­men­tal Alzheimer’s ther­a­py ad­u­canum­ab — and its deal­mak­ing team knows it.

In twin deals an­nounced on Fri­day, Bio­gen $BI­IB is ty­ing up with Sky­hawk Ther­a­peu­tics to ex­plore small mol­e­cule RNA splic­ing mod­i­fiers for spinal mus­cu­lar at­ro­phy and sign­ing on C4 Ther­a­peu­tics to re­search the ap­pli­ca­tion of pro­tein degra­da­tion tech in Alzheimer’s — among oth­er ear­ly-stage projects in neu­rol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER